BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 20808046)

  • 1. [Dementia and fracture].
    Sato Y
    Clin Calcium; 2010 Sep; 20(9):1379-84. PubMed ID: 20808046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prevention of hip fracture with menatetrenone and risedronate plus calcium supplementation in elderly patients with Alzheimer disease: a randomized controlled trial.
    Sato Y; Honda Y; Umeno K; Hayashida N; Iwamoto J; Takeda T; Matsumoto H
    Kurume Med J; 2011; 57(4):117-24. PubMed ID: 21778673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease: a randomized controlled trial.
    Sato Y; Kanoko T; Satoh K; Iwamoto J
    Arch Intern Med; 2005 Aug 8-22; 165(15):1737-42. PubMed ID: 16087821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of hip fractures by exposure to sunlight and pharmacotherapy in patients with Alzheimer's disease.
    Iwamoto J; Sato Y; Tanaka K; Takeda T; Matsumoto H
    Aging Clin Exp Res; 2009; 21(4-5):277-81. PubMed ID: 19959915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease.
    Sato Y; Honda Y; Iwamoto J
    Neurology; 2007 Mar; 68(12):911-5. PubMed ID: 17372126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke.
    Sato Y; Iwamoto J; Kanoko T; Satoh K
    Arch Intern Med; 2005 Aug 8-22; 165(15):1743-8. PubMed ID: 16087822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amelioration of osteoporosis and hypovitaminosis D by sunlight exposure in Parkinson's disease.
    Sato Y; Iwamoto J; Honda Y
    Parkinsonism Relat Disord; 2011 Jan; 17(1):22-6. PubMed ID: 21050796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of non-vertebral fracture between minodronate and risedronate therapy in elderly female patients with Alzheimer disease.
    Sato Y; Honda Y; Iwamoto J; Amano N
    J Musculoskelet Neuronal Interact; 2013 Sep; 13(3):346-52. PubMed ID: 23989256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risedronate therapy for prevention of hip fracture after stroke in elderly women.
    Sato Y; Iwamoto J; Kanoko T; Satoh K
    Neurology; 2005 Mar; 64(5):811-6. PubMed ID: 15753414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Osteoporosis in the elderly--diagnosis and treatment].
    Gärtner R
    MMW Fortschr Med; 2005 Feb; 147(7):33, 35-6. PubMed ID: 18441582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.
    McClung MR; Geusens P; Miller PD; Zippel H; Bensen WG; Roux C; Adami S; Fogelman I; Diamond T; Eastell R; Meunier PJ; Reginster JY;
    N Engl J Med; 2001 Feb; 344(5):333-40. PubMed ID: 11172164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amelioration of osteoporosis and hypovitaminosis D by sunlight exposure in hospitalized, elderly women with Alzheimer's disease: a randomized controlled trial.
    Sato Y; Iwamoto J; Kanoko T; Satoh K
    J Bone Miner Res; 2005 Aug; 20(8):1327-33. PubMed ID: 16007329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of treatment modalities for postmenopausal osteoporosis.
    Hamdy RC; Chesnut CH; Gass ML; Holick MF; Leib ES; Lewiecki ME; Maricic M; Watts NB
    South Med J; 2005 Oct; 98(10):1000-14; quiz 1015-7, 1048. PubMed ID: 16295815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once-weekly risedronate for prevention of hip fracture in women with Parkinson's disease: a randomised controlled trial.
    Sato Y; Iwamoto J; Honda Y
    J Neurol Neurosurg Psychiatry; 2011 Dec; 82(12):1390-3. PubMed ID: 21825080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of risedronate on the risk of hip fracture in elderly women.
    Schott AM; Dargent-Molina P; Meunier PJ
    N Engl J Med; 2001 May; 344(22):1721. PubMed ID: 11386284
    [No Abstract]   [Full Text] [Related]  

  • 17. Nutritional aspects of hip fractures.
    Bonjour JP; Schurch MA; Rizzoli R
    Bone; 1996 Mar; 18(3 Suppl):139S-144S. PubMed ID: 8777079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amelioration of osteoporosis by menatetrenone in elderly female Parkinson's disease patients with vitamin D deficiency.
    Sato Y; Honda Y; Kaji M; Asoh T; Hosokawa K; Kondo I; Satoh K
    Bone; 2002 Jul; 31(1):114-8. PubMed ID: 12110423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bisphosphonate treatment prevents hip fractures in 70-79 year old women with osteoporotic vertebral fractures].
    Netelenbos JC
    Ned Tijdschr Geneeskd; 2001 Jul; 145(28):1336-8. PubMed ID: 11484428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risedronate therapy for prevention of hip fracture after stroke in elderly women.
    Poole KE; Warburton EA; Reeve J
    Neurology; 2005 Nov; 65(9):1513-4; author reply 1513-4. PubMed ID: 16275859
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.